Adlai Nortye Group Ltd. American Depositary Shares ANL
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $30.80 (+97.2% upside)
Key Stats
- Today's Range
- $14.87 – $16.73
- 50-Day Range
- $12.10 – $16.95
- 52-Week Range
- $0.88 – $17.25
- Volume
- 300K shs
- Average Volume
- 192K shs
- Market Cap
- $998.81 million
- P/E Ratio
- —
- Dividend Yield
- 6.40%
Dividend
- Dividend Yield
- 6.40%
- Annual Dividend
- $1.00
- Payout Ratio
- —
- Ex-Dividend Date
- 2008-08-13
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Adlai Nortye Group Ltd. American Depositary Shares
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Related Stocks
Compare head-to-head: ANL vs NVDA·ANL vs AAPL·ANL vs GOOGL·ANL vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.